Current Therapeutic Research-clinical and Experimental最新文献

{"title":"Understanding Pharmacokinetic-Drug Interactions With Drugs Approved by the US Food and Drug Administration in 2024 to Better Manage the Risk of Drug Interactions With Concomitant Medications: A Review of Clinical Data From New Drug Applications","authors":"Jingjing Yu MD, PhD,&nbsp;Sophie Argon PharmD,&nbsp;Katie Owens BPharm, PhD,&nbsp;Yan Wang MS,&nbsp;Isabelle Ragueneau-Majlessi MD, MS","doi":"10.1016/j.curtheres.2025.100818","DOIUrl":"10.1016/j.curtheres.2025.100818","url":null,"abstract":"<div><h3>Objective</h3><div>This analysis aimed to provide a mechanistic understanding and an evaluation of the clinical relevance of pharmacokinetic drug-drug interactions (DDIs) associated with drugs approved by the Food and Drug Administration in 2024.</div></div><div><h3>Methods</h3><div>Drug metabolism, transport, and absorption-based DDI data available in New Drug Applications (NDAs) of small molecular drugs approved (<em>n</em> = 34) was analyzed. The mechanism and clinical outcome of these interactions were characterized based on <em>in vitro, in silico</em>, and clinical data.</div></div><div><h3>Results</h3><div>As objects, 11 drugs were identified as clinical substrates. Of these, 7 drugs were substrates of CYP3A, 3 of CYP2C9, one of CYP1A2, and one of CYP2C8, including the sensitive substrates vanzacaftor (CYP3A) and vorasidenib (CYP1A2). As precipitants, 6 drugs (acoramidis, cefepime/enmetazobactam, givinostat, lazertinib, mavorixafor, and resmetirom) were clinical inhibitors of CYP enzymes (2C8, 2C9, 2D6, 2E1, and 3A), with mavorixafor being a CYP2D6 strong inhibitor. Two drugs (elafibranor and tovorafenib) showed weak induction of CYP3A. Regarding transporter data, 3 drugs were substrates of transporters, including seladelpar (BCRP and OAT3), sulopenem (OAT3), and vadadustat (OAT1/3), and 8 drugs (arimoclomol, danicopan, givinostat, lazertinib, mavorixafor, resmetirom, vadadustat, and vazacaftor/tezacaftor/deutivacaftor) were inhibitors of transporters. All clinical DDIs with AUC changes ≥ 2-fold triggered labeling recommendations. Several DDIs with an AUC change &lt;2 also had labeling recommendations, pertaining most often to the concomitant use of drugs with a narrow therapeutic index.</div></div><div><h3>Conclusions</h3><div>Mechanistic DDI insights from newly approved therapies can be extrapolated to inform the management of commonly co-administered drugs, supporting a safer and more effective use of new drug products in the context of polypharmacy.</div></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"104 ","pages":"Article 100818"},"PeriodicalIF":1.5,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145924016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Insomnia and Its Therapeutic Approaches Among University Students in Madrid","authors":"Alejandro Martínez Lledín MD ,&nbsp;Marta Mora Massó MD ,&nbsp;Ana Oliva Sánchez MD, PhD ,&nbsp;Sandra Pérez Hernández MD ,&nbsp;Paula Prada Sanz MD ,&nbsp;Francisco Abad-Santos MD, PhD","doi":"10.1016/j.curtheres.2025.100815","DOIUrl":"10.1016/j.curtheres.2025.100815","url":null,"abstract":"<div><h3>Purpose</h3><div>Insomnia is a common sleep disorder that affects students’ academic performance and quality of life. This study aims to assess the prevalence of insomnia among students from various degrees enrolled at several universities in Madrid, examine the factors influencing its prevalence, and evaluate the different methods students use to alleviate the problem.</div></div><div><h3>Methods</h3><div>We conducted a cross-sectional study using an anonymous “Google Forms” survey that included a validated insomnia questionnaire and additional relevant questions. The survey was distributed online, and we collected 414 responses, of which 408 were valid.</div></div><div><h3>Findings</h3><div>Of these, 44 students (10.8%) reported moderate insomnia, and 3 (0.7%) severe insomnia. Insomnia was more frequent among women (13.8% of 298 women) compared to men (4.6% of 108 men) (<em>P</em> = 0.01). There were no significant differences between different degree programs or between lower and higher year students. Academic performance and mood were lower in students with insomnia. Thirty students (7.4%) reported using medications to aid sleep, such as melatonin or benzodiazepines; 66 (16.2%) used herbal products, and 24 (5.9%) used both. Of the students with insomnia, 28 (59.6%) used medications or herbal products, compared to 92 (25.5%) of those without insomnia (<em>P</em> &lt; 0.001).</div></div><div><h3>Implications</h3><div>We conclude that 11.5% of students suffer from insomnia, and 40% of them do not receive any treatment, indicating a need for improved diagnostic measures and increased treatment options.</div></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"104 ","pages":"Article 100815"},"PeriodicalIF":1.5,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145898004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effects of Yacon Consumption on Body Weight and C-reactive Protein: A Systematic Review and Meta-analysis of Randomized Controlled Trials","authors":"Fariborz Porbafrani PhD ,&nbsp;Mohammad Samadi PhD ,&nbsp;Karim Parastouei PhD","doi":"10.1016/j.curtheres.2025.100817","DOIUrl":"10.1016/j.curtheres.2025.100817","url":null,"abstract":"<div><h3>Background</h3><div>The rising global challenges of obesity and chronic inflammation contribute to an increased prevalence of metabolic disorders and cardiovascular diseases.</div></div><div><h3>Objective</h3><div>The goal of the meta-analysis of randomized controlled trials (RCTs) was to assess the impact of yacon consumption on body weight and levels of C-reactive protein (CRP).</div></div><div><h3>Methods</h3><div>Online databases such as PubMed/Medline, Scopus, Web of Science, and Google Scholar were searched until June 2024 to collect RCTs that investigated the impact of yacon consumption on body weight and CRP. Meta-analyses were conducted using a random-effects model, and the <em>I</em>² index was employed to evaluate the heterogeneity among the RCTs.</div></div><div><h3>Results</h3><div>Seven studies with a total of 246 participants were included in the study. The pooled effect size indicated that yacon intake was associated with weight reduction (weighted mean difference [WMD], −8.22 kg; 95% CI, −16.01 to −0.43; <em>P</em> = .039). In contrast, yacon consumption showed no significant effects on body mass index (BMI) (WMD, −1.48 kg/m²; 95% CI, −4.11 to 1.14; <em>P</em> = .268), waist circumference (WC) (WMD, −3.73 cm; 95% CI, −10.18 to 2.72; <em>P</em> = .257), and CRP (WMD, −0.07 mg/L; 95% CI, −1.96 to 1.81; <em>P</em> = .939). Subgroup analyses demonstrated that yacon consumption led to significant weight reductions in individuals aged 40 years and older, as well as in women and those who consumed yacon for more than 8 weeks. Additionally, yacon consumption was associated with reductions in BMI and WC in women and individuals aged &gt;40 years. However, no statistically significant differences were observed for other factors.</div></div><div><h3>Conclusions</h3><div>The findings suggest that yacon consumption may contribute to weight reduction in adults, though effects on BMI, WC, and CRP remain uncertain.</div></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"104 ","pages":"Article 100817"},"PeriodicalIF":1.5,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146178257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Facts and Issues of Submitting Applications (Public Knowledge-Based Applications) for Unapproved and Off-label Drugs With High Medical Needs in Japan","authors":"Akiko Hinomura MA ,&nbsp;Daisuke Obata MD, PhD ,&nbsp;Jun Matsubayashi MS, MPH ,&nbsp;Mayumi Yamanaka MPH ,&nbsp;Koji Yamada MS ,&nbsp;Rumiko Hosoki PhD ,&nbsp;Hiromu Kutsumi MD, PhD ,&nbsp;Shin-ya Morita PhD ,&nbsp;Shu Kasama MD, PhD","doi":"10.1016/j.curtheres.2025.100819","DOIUrl":"10.1016/j.curtheres.2025.100819","url":null,"abstract":"<div><h3>Background</h3><div>In Japan, to promote the development and application of unapproved and off-label drugs, a review pathway known as the “public knowledge-based application” was established in 1999. This pathway allows companies to submit applications without clinical trials if the drug has publicly known efficacy and safety and is deemed highly necessary for medical purposes.</div></div><div><h3>Objective</h3><div>The aim of this study is to analyze information published on government websites and to clarify what the criteria for “public knowledge” or “medically necessary” that apply to “public knowledge-based application” that are not yet clear.</div></div><div><h3>Methods</h3><div>We analyzed the correlation between the evidence presented in applications and the progression from the determination of high medical needs to regulatory approval for unapproved and off-label drugs requested for development by patient groups and academic societies in Japan between August 2013 and March 2022.</div></div><div><h3>Results</h3><div>Of the 171 requests, 54 were judged to meet the criteria for medical necessity, and 25 of these were judged to meet the criteria for public knowledge-based application. Of the requests that did not meet the criteria for medical necessity, 90% involved existing domestic therapies. Seventy-two percent of requests meeting the public knowledge-based application criteria involved drugs with standard use in 6 Western countries.</div></div><div><h3>Conclusion</h3><div>This study suggests that the availability of existing domestic therapies and the approval or standard use status of a drug in the 6 Western countries influence the judgment of the applicability of public knowledge-based applications.</div></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"104 ","pages":"Article 100819"},"PeriodicalIF":1.5,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146074084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Compatibility and Stability of Cipepofol (Ciprofol) and Etomidate Mixture for Intravenous Anesthesia","authors":"Linzhong Zhang MD ,&nbsp;Lingchun Kong MA ,&nbsp;Qi Deng MS ,&nbsp;Yukai Chao MA ,&nbsp;Chibing Fu MA ,&nbsp;Yutong Meng MA","doi":"10.1016/j.curtheres.2025.100810","DOIUrl":"10.1016/j.curtheres.2025.100810","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the physical and chemical compatibility and stability of a cipepofol (ciprofol) and etomidate (EC) mixture for intravenous anesthesia and assess the physiochemical stability of the drugs during co-administration through the same intravenous line.</div></div><div><h3>Methods</h3><div>High-performance liquid chromatography and other analytical techniques were employed to investigate the stability of the EC mixture. The mixture was prepared and stored at 4°C, 25°C, or 37°C for 24 h, and its appearance, pH, osmotic pressure, particle size, zeta potential, drug content, and related substances were evaluated at 0, 1, 3, 6, 12, and 24 h.</div></div><div><h3>Results</h3><div>The EC mixture maintained physical stability, with no significant changes in appearance, pH (fluctuation, ≤0.07 units), osmotic pressure (relative standard deviation [RSD] &lt; 2.0%), or particle size observed over 24 h. Zeta potential remained within acceptable limits (ranging from −40 to −30 mV), indicating good colloidal stability. Chemically, drug content remained at ≥99.9% of the initial level (RSD &lt; 1.2%), and impurity levels stayed within the specified limits (maximum single impurity ≤ 0.13%, total impurities ≤ 0.37%).</div></div><div><h3>Conclusions</h3><div>The findings suggest that the EC mixture was physically and chemically compatible and stable for up to 24 h at various temperatures, making this regimen a potentially safe and effective option for intravenous anesthesia. This finding is significant for improving patient comfort and reducing adverse drug reactions during anesthesia induction and maintenance.</div></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"103 ","pages":"Article 100810"},"PeriodicalIF":1.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144889037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Emblica officinalis (Amla) Extract Versus Exercise on Lipid Levels in Participants With Abnormal Lipid Levels: An Open-Label Clinical Study","authors":"Kiran Jagalurappa MD ,&nbsp;Giriraja Kanakapura Vrushabaiah MD ,&nbsp;Suman Govindaraj BDS","doi":"10.1016/j.curtheres.2025.100800","DOIUrl":"10.1016/j.curtheres.2025.100800","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;Dyslipidemia, marked by abnormal lipid levels, significantly increases the risk of cardiovascular diseases. Effective management of these lipid abnormalities is essential for reducing cardiovascular risk. &lt;em&gt;Emblica officinalis&lt;/em&gt;, known as amla in Ayurveda, is traditionally considered the best fruit due to its numerous health benefits.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;div&gt;To evaluate the efficacy and tolerability of amla extract on participants with abnormal lipid levels and compare with the effect of physical activity in reducing atherogenic factors.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;Forty-five inactive participants having abnormal lipid levels were selected and instructed to initiate lifestyle changes, including a healthy diet and aerobic exercise for 14 days. Thirty-nine participants who met the study criteria even after exercise were allocated a 500 mg capsule of amla extract (Tri-Low®) twice daily for 90 days. The effect of amla extract on lipid parameters, atherogenic index of plasma (AIP), apolipoprotein (Apo) B/Apo A ratio, high-sensitivity C-reactive protein, coenzyme Q10, and hydroxy methylglutaryl coenzyme A reductase levels was studied and compared with the effect of physical activity or exercise on these parameters. Laboratory parameters, global tolerability, and treatment-emergent adverse events were evaluated for the assessment of safety profile of amla extract.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;Amla extract over a period of 90 days significantly reduced triglyceride (&lt;em&gt;P&lt;/em&gt; = 0.007), total cholesterol (&lt;em&gt;P&lt;/em&gt; &lt; 0.001), LDL (&lt;em&gt;P&lt;/em&gt; = 0.006), VLDL (&lt;em&gt;P&lt;/em&gt; = 0.014), and AIP (&lt;em&gt;P&lt;/em&gt; &lt; 0.001) but reported no significant effect on HDL (&lt;em&gt;P&lt;/em&gt; = 0.967) and fasting blood sugar (&lt;em&gt;P&lt;/em&gt; = 1.00). Varying the intensity of exercise from low to moderate and high had no significant effect on triglyceride (&lt;em&gt;P&lt;/em&gt; = 0.516), total cholesterol (&lt;em&gt;P&lt;/em&gt; = 0.676), LDL (&lt;em&gt;P&lt;/em&gt; = 0.511), VLDL (&lt;em&gt;P&lt;/em&gt; = 0.454), or AIP (&lt;em&gt;P&lt;/em&gt; = 0.472). However, LDL exhibited a significant reduction with amla extract, combined with exercise (&lt;em&gt;P&lt;/em&gt; &lt; 0.001). Apolipoprotein B/Apo A1 ratio exhibited a trend toward significance (&lt;em&gt;P&lt;/em&gt; = 0.061). Weight and reductions were statistically significant with amla extract and exercise, after 45 days (&lt;em&gt;P&lt;/em&gt; &lt; 0.001) and 90 days (&lt;em&gt;P&lt;/em&gt; = 0.002). Hydroxy methylglutaryl coenzyme A, Apo B, and coenzyme Q10 exhibited no significant changes. Overall, it was evident that the significant changes in lipid parameters are attributable to amla extract rather than physical activity alone. All other factors are not affected by exercise intensity, and the significant changes observed are purely due to the effect of amla extract.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;Exercise alone is often insufficient for optimal cardiovascular health. The supplementation of amla extract (Tri-Low®) from this study reported significant potential","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"103 ","pages":"Article 100800"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144365194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cognitive Effect of Levetiracetam in Patients with Alzheimer’s Disease or Mild Cognitive Impairment: A Systematic Review","authors":"Mohamad Hosein Mohamadi MD ,&nbsp;Amir Bavafa PhD ,&nbsp;Sahar Salehi PhD ,&nbsp;Mahsa Abedi MSc ,&nbsp;Fahimeh Shahabi MSc ,&nbsp;Sana Jafarlou MD ,&nbsp;Pirhossein Kolivand PhD ,&nbsp;Sajad Sahab-Negah PhD","doi":"10.1016/j.curtheres.2025.100798","DOIUrl":"10.1016/j.curtheres.2025.100798","url":null,"abstract":"<div><h3>Background</h3><div>Various therapeutic interventions have been investigated for cognitive impairment, a common problem in Alzheimer’s disease (AD). Levetiracetam (LEV), an antiepileptic drug, has been shown to alleviate cognitive impairment.</div></div><div><h3>Objective</h3><div>The present systematic review aimed to evaluate the cognitive effects of LEV in patients with AD or mild cognitive impairment (MCI).</div></div><div><h3>Methods</h3><div>We searched PubMed/MEDLINE, Scopus, Web of Sciences, and Embase databases for all studies on LEV and cognitive impairment. After multistep screening, we identified qualified interventional studies and performed further data extraction. We reviewed the methodological diversity across the studies and assessed the quality of each study using the critical appraisal of the Joanna Briggs Institute checklist (the risk of bias assessment).</div></div><div><h3>Results</h3><div>Of the 1091 publications, only 5 articles were qualified for review. All studies enrolled patients with AD or MCI, and at least 1 arm of the trial involved LEV therapy. Four of 5 studies reported significant cognitive improvement in patients with AD or MCI after the LEV trials, whereas 1 study found no significant change in cognitive status. The risk of bias assessment revealed that 4 studies had a low risk of bias. Among them, 3 showed significant improvement, whereas 1 did not report a significant change in cognitive function.</div></div><div><h3>Conclusions</h3><div>The efficacy of LEV therapy for cognitive impairment varies across studies owing to different methodologies, dosages, treatment durations, and outcome assessment tools. This study suggests that LEV may exert a beneficial impact on cognitive function in patients with AD or MCI. However, a quantitative comparison or meta-analysis is essential to draw definitive conclusions about the cognitive effects of LEV in AD and MCI.</div></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"103 ","pages":"Article 100798"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144297128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pumpkin Seeds as a Natural Remedy for Anemia: Nutritional Insights and Therapeutic Potential","authors":"Andugula Swapna Kumari MSc ,&nbsp;Gowrishankar Arumugam MD ,&nbsp;Shyamaladevi Babu MPhil, PhD ,&nbsp;Madhan Krishnan MSc, PhD ,&nbsp;Nohini Sandhya Singampalli M.Sc ,&nbsp;Jayanthi Chandramohan M.Sc","doi":"10.1016/j.curtheres.2025.100797","DOIUrl":"10.1016/j.curtheres.2025.100797","url":null,"abstract":"<div><div>Anemia is a widespread global health concern characterized by reduced hemoglobin levels and diminished oxygen-carrying capacity of the blood. According to the World Health Organization, anemia affects 40% of children aged 6 to 59 months, 37% of pregnant women, and 30% of women aged 15 to 49 years globally. The condition is primarily linked to iron deficiency, particularly in low- and middle-income countries, although other factors such as vitamin B12 insufficiency, parasitic infections, chronic diseases, and genetic disorders also contribute. The socioeconomic and health impacts of anemia highlight the need for effective prevention and management strategies. Dietary interventions play a critical role in addressing iron deficiency, with functional foods gaining prominence for their sustainable and cost-effective potential. Among these, pumpkin seeds (<em>Cucurbita</em> spp) stand out due to their rich nutrient profile and potential health benefits. This review explores the global and Indian prevalence of anemia, the nutritional complexity of the condition, and the therapeutic potential of pumpkin seeds. It discusses their nutritional composition, mechanisms of action, and current evidence supporting their role in combating anemia while identifying research gaps and future directions for establishing standardized dietary recommendations. Much literature and scientific research underscore the importance of nutrient-dense foods such as pumpkin seeds, which are rich in essential micronutrients such as iron, zinc, magnesium, and bioactive compounds that support hematopoiesis and overall health. Leveraging the therapeutic potential of these natural alternatives, alongside fortified food programs and precise monitoring methods, can significantly contribute to anemia reduction and improve public health outcomes.</div></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"103 ","pages":"Article 100797"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144230488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tarlatamab and the Future of Immunotherapy: A New Approach to Small Cell Lung Cancer","authors":"Raza Ur Rehman MBBS,&nbsp;Ahmad Furqan Anjum MBBS,&nbsp;Rida Fatima MBBS","doi":"10.1016/j.curtheres.2024.100773","DOIUrl":"10.1016/j.curtheres.2024.100773","url":null,"abstract":"","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"102 ","pages":"Article 100773"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11772990/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143058343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Adverse Effects and Tolerability of Dietary Ginger Supplementation in Patients With Functional Dyspepsia","authors":"Lemlem Gebremariam Aregawi PhD ,&nbsp;Csiki Zoltan MD, PhD","doi":"10.1016/j.curtheres.2025.100792","DOIUrl":"10.1016/j.curtheres.2025.100792","url":null,"abstract":"<div><h3>Background</h3><div>Functional dyspepsia (FD) is a prevalent upper gastrointestinal disorder characterized by chronic or recurrent symptoms, including epigastric pain, bloating, and nausea. Ginger (<em>Zingiber officinale</em>), a natural dietary supplement traditionally used to relieve gastrointestinal discomfort, has limited evidence regarding its safety and tolerability in patients with FD.</div></div><div><h3>Objective</h3><div>To evaluate the safety, tolerability, and adverse effects of ginger supplementation in patients with FD.</div></div><div><h3>Methods</h3><div>This open-label clinical trial was conducted at the Internal Medicine Outpatient Department, University of Debrecen. This study was conducted in full compliance with the ethical principles outlined in the Declaration of Helsinki. The study protocol was reviewed and approved by the Ethics Committee of the University of Debrecen (registry reference number: DE RKEB/IKEB 5622-2020). All participants provided written informed consent prior to their inclusion in the study. Fifty patients with FD were initially enrolled, and 47 participants completed the study. Ginger supplementation was administered at a dose of 1080 mg/d in divided doses over 8 weeks. Adverse effects were assessed weekly through clinical evaluations and self-reports, and tolerability was rated by participants at the end of the trial.</div></div><div><h3>Results</h3><div>The study included 47 patients with FD who completed the trial, with a mean (SD) age of 51.49 (14.64) years. Of the participants, 78.7% were females. Ginger supplementation was well tolerated, with mild and transient adverse effects reported, including bloating (14.9%), heartburn (12.8%), and diarrhea (10.6%). None of these adverse events necessitated discontinuation of the treatment. Tolerability was rated as good or excellent by 87.2% of participants, and no severe adverse events were observed.</div></div><div><h3>Conclusions</h3><div>Preliminary findings suggest ginger is well tolerated and may be a viable complementary dietary therapy, though further research is needed. ClinicalTrials.gov identifier: NCT06313814.</div></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"102 ","pages":"Article 100792"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143935151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}